Health Technology · Pharmaceuticals: Major · NSE: GLAXO · data 2026-10-09

GlaxoSmithKline Pharmaceuticals Limited

Health check: Strong (6.9/10 on quality, valuation vs sector, growth and momentum).

Open full analysis — chart, results, balance sheet, red flags →

Key figures

Price

₹2,540.3

Market cap

₹42,939 cr

P/E

40.3

P/B

—

ROE

49.1%

ROCE

52.8%

Debt / equity

0.01

Dividend yield

2.25%

1-year return

-6.9%

52-week high

₹3,120.7

52-week low

₹2,088.1

Operating margin

32.8%

Growth

Revenue (last 12 months)	₹3,955 cr
Net profit (last 12 months)	₹1,068 cr
Sales growth, 3 years (yearly)	5.5%
Profit growth, 3 years (yearly)	19.3%

Chart patterns

Double top — breakdown (key level ₹2,755.9)

Similar companies

Abbott India Limited (ABBOTINDIA) · Gland Pharma Ltd. (GLAND) · IPCA Laboratories Limited (IPCALAB) · Ajanta Pharma Limited (AJANTPHARM) · Emcure Pharmaceuticals Limited (EMCURE)

The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.

Open GLAXO in NSE Scanner →